Malaria vaccines

• Published in: Expert opinion on therapeutic patents Vol. 33; no. 3; p. 169
• Main Authors: Quagliata, Michael, Papini, Anna Maria, Rovero, Paolo
• Format: Journal Article
• Language: English
• Published: England 04.03.2023
• Subjects: Humans; Malaria - prevention & control; Malaria Vaccines; Malaria, Falciparum - parasitology; Malaria, Falciparum - prevention & control; Patents as Topic; Plasmodium falciparum; vaccine; antigen; malaria; Antibody; immune response
• ISSN: 1744-7674
• DOI: 10.1080/13543776.2023.2190884

Eradication of malaria remains one of the main aims of medicine. Despite progress in malaria treatment, mortality rate remains high, especially in the poorest parts of the world. Therefore, prevention through vaccines is fundamental and recent approval of the first effective vaccine reinforced this assumption. However, since the parasite cycle is composed of three stages, different types of vaccine targeting stage-specific antigens shall be developed. Moreover, the beneficial effect on vaccinated subjects can be tuned using compositions targeting different stages. We analyzed the malaria vaccine patent landscape describing the most significant patents published after 2016, classified according to the different parasite stages targeted focusing on selected protein antigens or epitopes. We searched 'malaria vaccine' on Patentscope and Espacenet. Pre-erythrocytic vaccines were boosted by RTS,S approval, but its partial efficacy, limited to sporozoites, calls for compositions active against other disease stages. In particular, multi-antigen vaccines could be more effective than single-stage ones, as they would activate an immune response similar to that acquired in endemic regions. Furthermore, vaccine storage is another factor to be considered given the climate of the areas where malaria is widespread. More advanced technologies can lead to more effective and safer vaccines.